Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$42.96 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)10.34M
Market Cap
$94.04B
Enterprise Value$131.71B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$50.93B
Price to Earnings (P/E)18.6
Beta0.25
Next Earnings
Oct 30, 2025EPS Estimate
1.69Last Dividend Ex-Date
Jul 03, 2025Dividend Yield5.32%
Share Statistics
EPS (TTM)1.46
Shares Outstanding2,035,435,800
10 Day Avg. Volume9,561,960
30 Day Avg. Volume10,344,324
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda8.73
Forecast
1Y Price Target
$50.79Price Target Upside9.94% Upside
Rating ConsensusHold
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe strong emerging data with iza-bren across multiple solid tumors suggests potential for driving strong outcomes when combined with PD-(L)1 antibodies.
Financial StabilityThe I/O and hematology businesses produce stable cash flows.
Market ShareThe strong MAPLE-HCM results for aficamten provide additional differentiation that could result in improvements in market share despite being second to market.
Bears Say
Clinical Trial UncertaintyThere are concerns about the ability of a VEGF mechanism to drive a meaningful overall survival benefit in a global study of NSCLC patients.
Internal ChallengesManagement decided to conduct internal reviews of trial site conduct and protocol adherence following multiple clinical trial failures.
Revenue ProjectionsCobenfy scripts are expected to miss Visible Alpha consensus estimates for 3Q25 revenue.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.96 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $94.04B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 30, 2025 which is in 44 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Aug 01, 2025. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.091 by $0.369.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 5.32%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.69.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,435,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.46 in its last earnings report, beating expectations of $1.091. Following the earnings report the stock price went up 2.124%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.79 (9.94% Upside)
$50.79 (9.94% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 88%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 350.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.28%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Company Deck
BMY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the growth portfolio and successful strategic initiatives, with increased revenue and earnings guidance. Despite challenges in the legacy portfolio and some study outcomes not meeting expectations, the company is well-positioned for long-term growth with a robust pipeline and strategic partnerships.View all BMY earnings summariesBMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
BMY Stock 12 Month Forecast
Average Price Target
$50.79
▲(9.94% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
22.95% Mutual Funds
15.97% Other Institutional Investors
35.26% Public Companies and Individual Investors